TABLE 1.
Demographic and imaging characteristics and quality scores of all studies included in the meta-analysis.
|
| ||||||||||||
| Authors (year of publication) | Method of analysis | N | Age in year (SD) | Gender (M/F) | Contrasts | Foci | Tal or MNI | MoCA | Education (years) | Scanner | Software | Quality scores (out of 9) |
| Kong et al. (2014) | fALFF | ESRD 64 | 34 (10) | 43/21 | ESRD < HCs | 12 | MNI | NA | NA | 3.0 T | SPM8 | 4/1/3 |
| HCs 45 | 31 (10) | 30/15 | ESRD > HCs | 0 | ||||||||
| Luo et al. (2016) | ALFF | ESRD 24 | 34 (8) | 16/8 | ESRD < HCs | 8 | MNI | NA | NA | 3.0 T | SPM8 | 4/1/3 |
| HCs 24 | 32 (9) | 16/8 | ESRD > HCs | 0 | ||||||||
| Li et al. (2018) | ALFF | ESRD 23 | 34 (8.7) | 16/7 | ESRD < HCs | 15 | Tal | 26.8 (2.7) | 11.9 (2.5) | 3.0 T | SPM8 | 4/2/2 |
| HCs 25 | 33 (10.3) | 17/8 | ESRD > HCs | 3 | 23.9 (2.5) | 12.9 (3.0) | ||||||
| Li et al. (2018) | ALFF | ESRD 28 | 34.1 (8.4) | 20/8 | ESRD < HCs | 16 | MNI | 23.94 (2.46) | 11.93 (2.51) | 3.0 T | SPM8 | 3/2/3 |
| HCs 25 | 32.8 (10.4) | 18/7 | ESRD > HCs | 0 | 26.87 (2.73) | 26.87 (2.73) | ||||||
| Chen et al. (2020) | ALFF | ESRD 19 | 45.2 (6.7) | 6/13 | ESRD < HCs | 2 | MNI | 25.0 (3.2) | 10.2 (2.7) | 3.0 T | DPARSF | 3/2/3 |
| HCs 17 | 41.8 (9.9) | 9/8 | ESRD > HCs | 2 | 27.1 (2.4) | 12.2 (3.0) | ||||||
| Jin et al. (2020) | ALFF | ESRD 46 | 53.11 (1.58) | 28/18 | ESRD < HCs | 2 | MNI | NA | NA | 3.0 T | DPARSF | 4/2/3 |
| HCs 47 | 55.57 (0.86) | 22/25 | ESRD > HCs | 2 | ||||||||
| Adil et al. (2021) | ALFF | ESRD 24 | 39.04 (11.84) | 15/9 | ESRD < HCs | 3 | MNI | NA | 9.71 (3.30) | 1.5 T | SPM12 | 4/2/2 |
| HCs 20 | 35.15 (6.07) | 7/13 | ESRD > HCs | 0 | 11.40 (3.02) | |||||||
| Guo et al. (2021) | ALFF | ESRD 42 | 51 (10.2) | 22/20 | ESRD < HCs | 7 | MNI | 22.5 (4.25) | 12 (3) | 3.0 T | DPABI | 4/2/2 |
| HCs 42 | 50 (10.0) | 22/20 | ESRD > HCs | 2 | 25.5 (4.25) | 9 (3) | ||||||
| Ma et al. (2021) | ALFF/fALFF | ESRD 31 | 46 (14) | 19/12 | ESRD < HCs | 3 | MNI | NA | 12.3 (2.7) | 3.0 T | REST plus | 3/2/3 |
| HCs 37 | 43 (12) | 20/17 | ESRD > HCs | 0 | 13.0 (3.0) | |||||||
| Peng et al. (2021) | ALFF | ESRD 24 | 56.21 (11.85) | 14/10 | ESRD < HCs | 20 | MNI | NA | 11.71 (3.45) | 1.5 T | SPM8 | 4/2/3 |
| HCs 27 | 50.74 (11.20) | 10/17 | ESRD > HCs | 0 | 12.04 (4.00) | |||||||
| Su et al. (2021) | ALFF | ESRD 20 | 37.1 (8.6) | 15/5 | ESRD < HCs | 2 | MNI | 25.4 (1.7) | 12.2 (2.8) | 3.0 T | DPARSF | 3/2/3 |
| HCs 17 | 38.5 (6.9) | 13/4 | ESRD > HCs | 1 | 26.6 (1.5) | 13.2 (3.1) | ||||||
ESRD, end-stage renal disease; ALFF, amplitude of low-frequency fluctuation; fALFF, fractional amplitude of low-frequency fluctuation; HCs, healthy controls; MNI, Montreal Neurological Institute; Tal, Talairach; MoCA, Montreal Cognitive Assessment; NA, not available; M, male; F, female; SD, standard deviation.